Multi-marker risk assessment of kidney sensitivity to injury to personalise prevention of acute kidney injury (SPAREKID) – Cancer Chemotherapy
About this trial
The Sparekid Study is currently open at:
- St. Luke’s Radiation Oncology Network (SLRON)
- The Mater Hospital
What is the goal of this study?
The purpose of this study is to better understand why some patients develop kidney damage after receiving certain chemotherapy drugs, and how we can predict this risk earlier.
This is an observational study which means patients treatment does not change and they won’t learn anything additional about their personal risk of kidney injury. All information collected in the study will be used to help us predict the risk of kidney injuries for future patients.
Some chemotherapy medications can put stress on the kidneys. At the moment, doctors can only tell that the kidneys are affected after damage has already happened. This study aims to change that by using blood and urine tests to examine markers related to genes, proteins, immune cells, and other indicators of kidney health.
The long-term aim is to create a test that can help identify patients who are more likely to develop kidney injury before treatment starts, allowing doctors to put protective measures in place or adjust treatment if needed.
What happens to patients as part of this trial?
If you join the study:
Before your first chemotherapy treatment
You will give one urine sample and one blood sample.
These will be taken at the same time as your routine pre-treatment bloods.
During your treatment
At each of your routine appointments (weekly during treatment) when you would be giving blood as part of standard care.
You will give one urine sample and one blood sample.
These samples are taken during your normal clinic visits so no extra hospital visits are needed.
After your treatment
The study team will look at your clinic letters, blood and urine test results and kidney function outcomes at 3 months, 6 months, and 12 months after your final chemotherapy dose.
No additional hospital visits are required.
Who can take part?
You may be eligible if:
- You are 18 years or older.
- You are receiving certain chemotherapy drugs that can affect the kidneys.
Study Oversight
Dr. Jennifer Gilmore is the Principal Investigator of the study in St. Luke’s Radiation Oncology Netowkr.
Professor Patrick T. Murray is the Chief Investigator for Ireland.
Prof. Stanislas Faguer is the International Principal Investigator and the study is sponsored by the University Hospital of Toulouse.